12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Other News

Array BioPharma hematology, cancer news

Array said it cut headcount by 20% to about 200 to focus development and commercialization resources on hematology and cancer programs. Array said the headcount reductions came mainly from its drug discovery organization, which the company now plans to fund through partnerships. The...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >